Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Sebastian Torke & Martin S. Weber. (2020) Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis. Expert Opinion on Investigational Drugs 29:10, pages 1143-1150.
Read now
Read now
Fortunato Morabito, Anna Grazia Recchia, Ernesto Vigna, Cirino Botta, Mamdouh Skafi, Mohammed Abu-Rayyan, Moien Atrash, Sara Galimberti, Lucio Morabito, Hamdi Al-Janazreh, Massimo Martino, Giovanna Cutrona & Massimo Gentile. (2020) An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. Expert Opinion on Pharmacotherapy 21:1, pages 29-38.
Read now
Read now
Piotr Smolewski, Dominika Rydygier & Tadeusz Robak. (2019) Clinical management of mantle cell lymphoma in the elderly. Expert Opinion on Pharmacotherapy 20:15, pages 1893-1905.
Read now
Read now
Articles from other publishers (5)
Daichi Akasaka, Satoru Iguchi, Ryusuke Kaneko, Yohei Yoshiga, Daisuke Kajiwara, Yoshinori Nakachi, Naruto Noma, Kenji Tanaka, Atsushi Shimizu & Fumihito Hosoi. (2023) Novel Bruton’s tyrosine kinase inhibitor TAS5315 suppresses the progression of inflammation and joint destruction in rodent collagen-induced arthritis. PLOS ONE 18:2, pages e0282117.
Crossref
Crossref
Christian Buske, Wojciech Jurczak, Joe-Elie Salem & Meletios A. Dimopoulos. (2022) Managing Waldenström’s macroglobulinemia with BTK inhibitors. Leukemia 37:1, pages 35-46.
Crossref
Crossref
Joshua S. Davis, David Ferreira, Emma Paige, Craig Gedye & Michael Boyle. (2020) Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clinical Microbiology Reviews 33:3.
Crossref
Crossref
Meng-zhen Lai, Pei-ran Song, Dou Dou, Yan-yan Diao, Lin-jiang Tong, Tao Zhang, Hua Xie, Hong-lin Li & Jian Ding. (2019) Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton’s tyrosine kinase inhibitors. Acta Pharmacologica Sinica 41:3, pages 415-422.
Crossref
Crossref
Diansong Zhou, Terry Podoll, Yan Xu, Ganesh Moorthy, Karthick Vishwanathan, Joseph Ware, J. Greg Slatter & Nidal Al‐Huniti. (2019)
Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite,
ACP
‐5862, Using a
Physiologically‐Based Pharmacokinetic
Modeling Approach
. CPT: Pharmacometrics & Systems Pharmacology 8:7, pages 489-499.
Crossref
Crossref